🇺🇸 tegafur-gimeracil-oteracil potassium in United States

92 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 92

Most-reported reactions

1. Decreased Appetite — 15 reports (16.3%)
2. Diarrhoea — 15 reports (16.3%)
3. Nausea — 11 reports (11.96%)
4. Anaemia — 9 reports (9.78%)
5. Interstitial Lung Disease — 9 reports (9.78%)
6. Neutropenia — 9 reports (9.78%)
7. Drug Ineffective — 7 reports (7.61%)
8. Malignant Neoplasm Progression — 6 reports (6.52%)
9. Pyrexia — 6 reports (6.52%)
10. Disease Progression — 5 reports (5.43%)

Source database →

Frequently asked questions

Is tegafur-gimeracil-oteracil potassium approved in United States?

tegafur-gimeracil-oteracil potassium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for tegafur-gimeracil-oteracil potassium in United States?

Fukushima Medical University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.